Home 2023 T2 Biosystems ($TTOO.O) Knightsbridge October Outlook

T2 Biosystems News in the Last Month

T2 Biosystems, Inc. (NASDAQ:TTOO), a clinical-stage biotechnology business, is creating novel molecular diagnostic assays to swiftly and correctly diagnose sepsis and other infectious disorders. The company’s solutions are made to assist physicians in better patient diagnosis and treatment, which improves patient outcomes and lowers healthcare costs.

T2 Biosystems has made a number of noteworthy announcements over the past month, including:

  • T2 Biosystems reported on September 19, 2023, that the FDA has approved 510(k) clearance for the T2Biothreat Panel, a quick molecular diagnostic test that can identify over 200 potential biothreat compounds in a single test. The T2Biothreat Panel is the first and only test of its kind to have received FDA clearance, and it is anticipated to be crucial in defending the general public’s health from biological threats.
  • Preliminary financial results for the third quarter of 2023 and business updates: T2 Biosystems declared on October 5, 2023, that it anticipated reporting preliminary third-quarter 2023 revenue of $1.5 million to $2.0 million, which would represent an increase of 50% to 100% compared to the previous year. The business added that it is on schedule to release its T2Bacteria Panel, a quick molecular diagnostic test for the identification of a wide variety of bacterial infections, in the fourth quarter of 2023.
  • Granting of incentive reward: T2 Biosystems revealed on October 6, 2023 that company had given an incentive reward to a new worker. The award consists of 120,000 RSUs, which will gradually vest over the course of four years.

T2 Biosystems has recently been active in the investment community in addition to the aforementioned news. On September 7, 2023, the company took part in the Gilmartin Group Emerging Growth Company Showcase. On October 23, 2023, it is slated to speak at the Jefferies Healthcare Conference.

T2 Biosystems has had a successful month overall, with several encouraging announcements and advancements. The business is in a good position to expand over the coming months and years.

This link offers a free 30-day trial of MetaStock.

Market Summary

T2 BIOSYSTMS ORD gapped up today on average volume (bullish). the potential for a runaway gap, which typically portends the trend will continue. There are four different categories of pricing gaps: Common, Breakaway, Runaway, and Exhaustion. A gap provides support or resistance.

T2 BIOSYSTMS ORD is now trending lower and is 48.3% below its 200-period moving average. In comparison to the average volatility over the previous ten periods, volatility is high. Our volume indicators show a roughly equal (neutral) volume flow into and out of TTOO.O. Our trend predicting oscillators have had a pessimistic outlook on TTOO.O for the previous 23 periods. The security price has not matched the new 14-period high that our momentum oscillator has set. A bullish divergence has occurred.

Technical Outlook
Short Term: Neutral
Intermediate Term: Bearish
Long Term: Bearish

The current value for the 14 period RSI is 51.8287.


Because prices closed lower than they opened, there was a black body.
There have been 5 white candles and 5 black candles throughout the last 10 bars. There have been 22 white candles and 28 black candles during the course of the last 50 bars, for a net of 6 black candles.

There was a long upper shadow. Generally speaking, this is a bearish indication (especially if it appears close to a high price level, at a resistance level, or when the asset is overbought).

When the top of the previous shadow is lower than the bottom of the current shadow, there is a rising window. This typically means that a positive trend will continue. In the past 50 candles, there have been 7 rising windows, making the current rising window even more bullish.

Bollinger Bands by MetaStock

T2 BIOSYSTMS ORD(Trade Price) closed 41.1% below the upper band on 10/9/2023.

The Bollinger Bands are 43.08% smaller than they should be. The bands’ small width, compared to the typical range of the T2 BIOSYSTMS ORD(Trade Price), shows minimal volatility. As a result, there is now a greater likelihood that volatility may rise along with a sudden price change in the near future. The bands have spent 14 period(s) in this restricted range. The longer the bands stay in this constrained range, the greater the chance of a big price change.

Relative Strength Index (RSI) activity and recent price behavior around the bands do not currently indicate any trading opportunities.

You may also like


Your Trusted Source for Capital Markets & Related News

© 2023 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.